Vol 50 No 04

"My experience with patients who are on surveillance, who meet the criteria for active surveillance, [is that they] tend to be younger and healthier patients, so I don’t see why not," says one urologist.

"It’s important to recognize that there has been a shift in the way we approach ADT," says David F. Jarrard, MD.

Urologists are the principal drivers of utilization for 14 drugs.

Most states require affidavits for malpractice cases to proceed.

"Although it might be easier to enumerate the cancer conditions, in the benign world, struggles continue to overcome patients challenged with these conditions," writes Gopal H. Badlani, MD.

Pathologic tissue confirmation is usually the best practice.

"If adequate cancer control can be achieved by focal or partial-gland treatment, then the favorable adverse event profile could make this a preferred option for a number of men with localized intermediate-risk (and possibly selected high-risk) prostate cancer," writes Badar M. Mian, MD.

A study presented at the 2022 Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Winter Meeting evaluated the safety and efficacy of percutaneous tibial nerve stimulation (PTNS) in patients who suffer from female sexual dysfunction.

5-year results from the pivotal WATER trial showed IPSS improvement was greater with Aquablation compared with TURP.

In this interview, Caleb Nelson, MD, PhD, discusses the current state of evaluation and treatment of stones in pediatric patients.

The combination of the PD-L1 inhibitor avelumab and the tyrosine kinase inhibitor axitinib showed promise as a neoadjuvant therapy for patients with high-risk, non-metastatic clear-cell renal cell carcinoma, according to findings from the NeoAvAx trial.

The combo of the PARP inhibitor niraparib and the multikinase inhibitor cabozantinib showed positive early efficacy and safety signals in patients with metastatic urothelial carcinoma or renal cell carcinoma.

In this interview, Polina X. Reyblat, MD, discusses the ways in which urologists can make their practices a more comfortable and open environment for patients of all different backgrounds to receive care.

In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Veda N. Giri, MD, highlights the role genetic testing has played in a new era of prostate cancer therapeutics.